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and items. Feedback on the questionnaire was also obtained from the  
patient interviewers, clinical experts and a translation expert. The conceptual 
framework and questionnaire were subsequently revised. RESULTS:  
The conceptual framework represents functional reading independence  
as a unidimensional concept. Eleven functional reading activities have a  
direct effect on functional reading independence: 1) reading written print; 2) 
reading to pay bills or write a check; 3) reading in order to take medicine; 4) 
reading instructions; 5) reading labels; 6) reading to play games; 7) reading to 
make or receive a telephone call; 8) reading words or numbers on the screen 
while watching television; 9) reading when using a computer; 10) reading street 
signs; and 11) reading signs for directions. The process of performing each 
functional reading activity may be completely independent, or may involve the 
use of vision aids, behavior changes to accommodate vision problems, and/or 
receiving help from another person. CONCLUSIONS: To our knowledge, this is 
the first conceptual framework specifically representing functional reading 
independence from the perspective of patients with GA. The conceptual 
framework may evolve once empirical evidence is available. The questionnaire 
based on the conceptual framework is currently being tested in a Phase II clinical 
trial.  
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OBJECTIVES: Wet Age-related Macular Degeneration (wAMD) is one of the major 
causes of visual impairment in Japan. However the patient burden from wAMD 
has not been widely reported. The objective of this study was to characterize 
how Japanese wAMD patients are affected by the disease. METHODS: This is a 
multi-site observational study across Japan on wAMD patients who have 
received medical treatment during the past 12 months. Collected patient-
reported outcome measures included Quality of Life using the National Eye 
Institute Visual Functioning Questionnaire-25 (NEI-VFQ-25) and depression scale 
by the Geriatric Depression Scale-Short Version-Japanese (GDS-S-J). Patients also 
reported on treatment satisfaction, caregiver assistance, and wAMD-associated 
comorbidities. RESULTS: Interim data for 211 patients are reported here; 97.2% of 
patients were 60 years of age and over. The mean score of NEI-VFQ-25 was 
68.19±17.84 and General Vision (45.78±18.07) was the lowest among 12 sub-
domains; 11.4% of patients had a score of 6 or above in GDS-S-J, indicating mild 
depression. A total of 38.4% and 45.5% of patients were dissatisfied with their 
treatment in terms on vision improvement and the time it takes for the 
treatment to work, respectively. A total of 10.4% of patients needed assistance 
with their daily tasks, but of those, only 4.7% had a caregiver to help them day-
to-day. 1.9% used paid services at home with the average of 1.3±0.47 hours per 
week; half of these patients used yearlong service and the rest used 6 months 
only; 5.9% of patients visited other doctors because of a fall which was related to 
their vision impairment. CONCLUSIONS: Our analyses showed that 38-45% of 
patients were dissatisfied with their current treatment. Very few patients who 
required assistance were able to have a caregiver to help them day-to-day. Paid 
services were also barely utilized.  
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OBJECTIVES: Manufacturers underestimate the time till reimbursement in the 
US for dermatology products and procedures. The purpose of this study was to 
examine the factors influencing time to reimbursement for different products 
and procedures and to identify strategies for ensuring optimal reimbursement 
status and CPT code valuation for such products, including consideration of the 
appropriate distribution channel. METHODS: The study involved 25 interviews 
with commercial medical and pharmacy directors, specialty pharmacy 
distributors, dermatologists and dermatology office managers. Interviews 
focussed on the perceptions and experiences of the interviewees in the 
prescribing of, and reimbursement for, new dermatology products and 
procedures. An analysis of historical coding evaluations for dermatological 
procedures was conducted and the challenges in building a valuation that is 
commercially viable were identified. RESULTS: Interviewees had multiple 
experiences of lacking the appropriate codes to secure reimbursement for the 
use of new dermatology products and procedures. These experiences have 
resulted in a situation where initial uptake of new products is out of line with 
the expectations of manufacturers. The process for informing the valuation of 
codes was considered to be highly politicised, with a need for extensive 
investment in supporting the case for the relative value units of a procedure. 
“Buy and bill” distribution routes were considered to be unsatisfactory from the 
point of view of dermatologist offices based. CONCLUSIONS: Manufacturers of 
new dermatology products that require the use of a procedure need to carefully 
consider their strategy for ensuring a reimbursement status and distribution 
route that enables dermatology offices to be reassured in using their product. A 
lack of planning may result in a total lack of uptake even for products that are of 
recognised clinical benefit.  
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OBJECTIVES: Ustekinumab is dosed at 45mg or 90mg (patient weight-dependent) 
in moderate-to-severe plaque psoriasis. The study objective was to assess 
observed increases (step-up from 45mg to 90mg) or decreases (step-down from 
90mg to 45mg) in ustekinumab dosing. METHODS: Truven Health MarketScan® 
Commercial and Medicare Supplemental databases were utilized to evaluate 
patients with: 1 ustekinumab index medical/pharmacy claim (09/25/2009-
10/31/2010); age ≥18 years at index; ≥ 6 months pre-index continuous enrollment; 
and ≥1 psoriasis diagnosis code (696.1) on or pre-index. Step-up and step-down 
dosing events and distribution of subsequent doses at each fill (doses 2-4) were 
assessed based on index dose received. Time to step-up or step-down was 
reported in days. RESULTS: Of 1,000 psoriasis patients receiving ustekinumab, 
step-up and step-down dosing events at anytime were evident in 9.9% (n=99) and 
6.8% (n=68), respectively. Median (mean±SD) time to step-up from index dose 
was 119 (113±76) days. Median (mean±SD) time to step-down from index dose 
was 49 (69±52) days. Of patients with step-up events, 37.4% returned to their 
original 45mg dose after step-up (mean=66 days). Of patients with step-down 
events, 39.7% returned to their original 90mg dose after step-down (mean=158 
days). Proportion of 45mg use by index 90mg patients spanned 6.1%-7.8% across 
doses. Proportion of 90mg use by index 45mg patients spanned 1.4%-16.8% 
across doses. CONCLUSIONS: In this observational study, <10% of psoriasis 
patients receiving ustekinumab had evidence of step-up/step-down dosing 
events at anytime. Over 1/3 of patients with either event returned to initial dose. 
Mean time to step-up was longer than mean time to step-down from initial dose 
by approximately 6 weeks. Step-up patients returned to lower initial dosing in a 
shorter period of time compared to step-down patients returning to higher initial 
dosing. Step-up/step-down dosing should be explored further in the context of 
weight, effectiveness, and safety.  
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HUNGARY  
Marada G, Nagy Á, Benke B, Molics B, Boncz I 
University of Pécs, Pécs, Hungary  
OBJECTIVES: The aim of this study was to assess the annual health insurance 
reimbursement of dental health service in counties and regions of Hungary. 
METHODS: The assessment base of the study was the annual reports of National 
Health Insurance Fund Administration (OEP). Only the data collected from the 
services in contractual relationship with the OEP and delivered between 2008 
and 2011 were evaluated. Our study covers primary, outpatient and hospital 
dental care.We analyzed the following indicators: number of cases(patients) per 
100 inhabitants, number of intervention (procedures) per 100 inhabitant, 
intervention per case, and reimbursement per intervention. RESULTS: Dental 
care was supplied by 3366 general and specialist dental care services at the end 
of 2011. The average number of cases per 100 inhabitants was 71 and varied 
between 55-95 in different counties. The average number of interventions per 
100 inhabitants was 199 and varied between 149-268 in different counties. The 
average number of interventions per case was 2.8 (2.56-3.13). The average 
reimbursement per intervention showed also significant differences among the 
counties (1018-1217) with an average of 1122 Hungarian Forint per case. Due to 
the progressive dental care system in those counties were university dental 
school can be found, the utilization of dental services is higher than in counties 
without dental school. CONCLUSIONS: Within the period under investigation, 
the health insurance reimbursement of dental care showed significant 
differences among counties and regions of Hungary. The presence of dental 
school is an important predictive factor for higher than national average 
utilization of dental services.  
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OBJECTIVES: Actinic keratoses are characterized by dysplastic epidermal lesions 
that occur in pale-skinned individuals chronically exposed to intense sunlight. It 
is one of the most commonly treated skin conditions but its prevalence in the 
Brazilian population is still unknown. The objective of this research is to describe 
the profile of the patients diagnosed with AK in São Paulo city. METHODS: A two 
months health survey was performed in the city of São Paulo in which 10 
dermatologists registered the profile of the patients diagnosed with actinic 
keratosis. RESULTS: The dermatologists saw 4961 patients in two months, 5,4% 
(269 patients), were diagnosed with AK (58% women). The mean age of the 
patients was 65 years old. 42% informed a family history of AK and 21% history 
of nonmelanoma skin cancer. Among the patients 80% of the participants 
belonged to the two initial categories of the Fitzpatrick Scale. 39% of the lesions 
were hyperkeratotic and the most common localizations of the lesions were face 
(35%) and the upper extremity (26%). Seventy-one percent of the patients were 
treated with surgical destruction of the lesions (chemical cautery, cryotherapy, 
electrocautery) and just 29% were prescribed to administer topical therapy (5-
fluourouracil, imiquimod, retinoic acid). CONCLUSIONS: The prevalence of 
actinic keratosis in this sample is 5,42%. The most affected sites were face and 
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upper extremity of these elderly patients with very fair skin. The preferred 
treatment was physical destruction of the lesions instead of noninvasive topical 
therapy.  
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OBJECTIVES: Actinic keratoses are common dysplastic epidermal lesions which 
occur in pale-skinned individuals who are chronically exposed to intense 
sunlight. It is one of the most commonly treated skin conditions. The objective of 
this research is to describe the Brazilian profile of solar exposition and the 
sunscreening agents use in patients with AK. METHODS: A two months health 
survey was performed in São Paulo city in which 10 dermatologists registered 
the profile of solar exposition and the sunscreening agents use of a sample of 
patients with AK. RESULTS: Of a total of 4961 patients, 269 (5,4%) patients were 
diagnosed with AK of which 58% were females. The mean age of the patients 
was 65 years old. Before AK diagnosis 91% of the patients exposed themselves to 
the sun mainly for leisure during weekends and only 26% used sunscreening 
agents. After AK diagnosis 43% of the patients still had the habit of solar 
exposition, however 78% uses sunscreening agents. The sun protection factor 
(SPF) most used before of the diagnosis was SPF15 (44%) and SPF30 (38%), 
changing to SPF30 (40%) and SPF60 (33%) after the diagnosis. CONCLUSIONS: 
This data suggest that the São Paulo city population with actinic keratosis 
presents the habit of leisure solar exposition with insufficient use of 
sunscreening agents. The use of sunscreening agents increases after the 
diagnosis of the disease.  
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OBJECTIVES: Overactive bladder (OAB) treatment guidelines recommend 
antimuscarinics as first-line pharmacologic therapy. Mirabegron is a first-in-
class beta-3 adrenoceptor agonist which is licensed for the treatment of OAB and 
has shown to be well tolerated and effective in the treatment of OAB symptoms. 
A systematic literature review and Mixed Treatment Comparisons (MTC) were 
performed to assess the efficacy and tolerability of OAB medications, and more 
specifically mirabegron 50 mg vs. antimuscarinics in patients with OAB. 
METHODS: This review included randomised controlled trials (RCTs) estimating 
changes in symptoms (micturition frequency, incontinence and urgency 
incontinence episodes) and probabilities of the most frequently reported adverse 
events associated with current OAB medications. Literature searches were 
performed on published peer reviewed articles from 2000 to 2012. The following 
drugs were considered in addition to mirabegron: tolterodine immediate release 
(IR) and extended release (ER), oxybutynin IR/ER, trospium, solifenacin, and 
fesoterodine. A Bayesian MTC was performed, with tolterodine ER 4 mg as 
reference comparator. RESULTS: 40 RCTs involving 26,033 patients were 
included. The deviance information criteria was minimised with the random 
effects model for dry mouth and with fixed effect model for other outcomes. The 
mixed treatment comparison showed that mirabegron 50mg had similar efficacy 
to most antimuscarinics in terms of micturition frequency, incontinence 
episodes and urgency urinary incontinence episodes. Mirabegron 50mg also had 
a probability of dry mouth similar to placebo, and significantly lower than all 
included antimuscarinics. CONCLUSIONS: Improvements of OAB symptoms 
were demonstrated for all reviewed OAB treatments versus placebo. Mirabegron 
50mg had similar efficacy to most antimuscarinics, and the lowest incidence of 
dry mouth, which is one of the main causes of discontinuation of 
antimuscarinics.  
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OBJECTIVES: To analyze the cost of treatment alternatives at different stages 
along kidney transplantation. METHODS: A Cost Analysis was developed to 
compare different treatment pathways alternatives for patients with kidney 
transplantation maintenance. Direct and Indirect costs were included. Four 
stages were identified for the cost analysis (induction, initial, maintenance and 
rejection). Each stage has different treatment alternatives, a combination of 
them were compared including medical services and drug costs. The perspective 
of the analysis was institutional. The resource use was identified by expert panel 
of clinicians, and medical literature. Cost valuation uses unitary cost list of the 
Mexican Institute of Social Security (IMSS). Drug costs are those from public 
tenders 2012. Initially, two scenarios were compared; the first was performed 
using the most common treatments available in the Institutions, the second 
scenario includes other alternatives. The first scenario alternatives were: Anti-
thymocyte globulin, a combination of Tacrolimus/Mycophenolate mofetil (MMF) 
and Cyclosporin/MMF for the induction, initial, and maintenance phase 
respectively. The second scenario were: Basiliximab, Cyclosporin/Everolimus and 
Cyclosporin/Mycophenolate Sodium (MPS). Hospital services, rejection treatment 
and diagnostic resources were the same for both scenarios. RESULTS: The costs 
for the different scenarios were lower in the second option than for the first case. 
In the first scenario the total cost per patient at all stages of kidney 
transplantation was US$40,210.28; with the second option was US$39,414.30; 
implying a cost saving of US$795.98 (2% less than the first option). 
CONCLUSIONS: From the perspective of the institution, it is important to review 
the treatment choices in order to achieve more efficiency in the resources use 
with the maximum effectiveness. The opportunity cost of the graft is high in the 
transplantation area.  
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OBJECTIVES: The main objective of the study is to compare and analyze the 
costs of various renal replacement interventions (dialysis, and renal 
transplantation). METHODS: A cross-sectional observational study was 
conducted at KIMS Hospital, Hyderabad, India for a period of six months. All the 
renal replacement therapy patients willingness to participate in the study was 
included. The data collected were cost of dialysis, renal transplantation, 
medications, consultation fee, transportation cost. We analyzed the average 
monthly and annual cost of Renal Replacement Therapies (RRT). RESULTS: A 
total of 100 patients were enrolled during the study period. Out of 100 patients, 
80 dialysis and 20 renal transplantation patients, majorities of them were in the 
age group of 41-60 year 66(66%) and men 63(63%) followed by women 37(37%). 
The cost for the dialysis for each time is Rs.1250. The average frequency of 
dialysis three times per week. The average monthly and annual cost of dialysis 
per patients was found to be Rs.15000 and Rs.1,80,000. The cost for the 
transplantation procedure was found to be Rs.1,40,000. The most commonly 
used Immunosuppressive agents were Tacrolimus, Mycophenolate Mofetil and 
Deflazacort. The average monthly costs of Immunosuppressive agents were 
Rs.8160-16000, Rs.2400-4800 and Rs.600-800 respectively. The average 
consultation fee for each time was found to be Rs.350. CONCLUSIONS: They are 
also several approaches to reduce the annual cost of renal replacement therapy 
(RRT). Obviously in long term, the most important factor is to reduce the number 
of patients with ESRD. This can be achieved by preventing the progression of 
renal disease. In India, the most frequent causes of ESRD are diabetes and 
hypertension. Early detection and treatment of these diseases play a vital role in 
the prevention of progression of renal failure and to postpone the need of RRT to 
an extent.  
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OBJECTIVES: To examine the economic burden and treatment patterns of 
chronic kidney disease (CKD) in the U.S. veteran population. METHODS: A 
retrospective database analysis was performed using the Veterans Health 
Administration (VHA) Medical SAS Datasets from October 1, 2005 to May 31, 2012. 
Patients diagnosed with CKD were identified using International Classification of 
Disease 9th Revision Clinical Modification (ICD-9-CM) diagnosis codes 585.xx, 
250.4xx, 791.0x, 583.xx, and 403.xx. Descriptive statistics were calculated as 
means ± standard deviation (SD) and percentages to measure treatment 
patterns, costs and utilization distribution in the sample. Treatment patterns 
were examined 60 days after the identification date, and costs and utilization 
were examined for the 1-year follow-up period. RESULTS: The total number of 
U.S. veterans diagnosed with CKD in the VHA study population from 2005 to 2012 
was 433,771. The top treatments for CKD patients were simvastatin (n=159,532, 
36.78%), lisinopril (n=135,660, 31.27%), omeprazole (n=93,449, 21.54%) and 
furosemide (n=90,114, 20.77%). Other treatments included insulin, metoprolol 
tartrate, and amlodipine besylate, all of which showed less than 20% of patient 
use. The top two comorbidities for CKD patients were hypertension and diabetes. 
The percentage of patients with follow-up inpatient visits was 27.23%, which 
translated into $11,927 in inpatient visit costs per patient. The percentage of 
patients with follow-up outpatient visits was 99.56%, incurring $8614 in 
outpatient costs per patient. Patients with pharmacy visits (94.61%) incurred 
$1869 in pharmacy costs. The average number of CKD patients with blood urea 
nitrogen test results was 349,750 (80.63%), and the test result mean was 27.01. 
The average number of CKD patients with creatinine estimated Glomerular 
Filtration Rate (eGFR) test results was 243,774 (56.20%) and the result mean was 
50.67. CONCLUSIONS: Inpatient costs for CKD patients were responsible for more 
than half of the total costs. Laboratory test results should always be considered 
when interpreting drug effects.  
